AU773928B2 - Compositions and methods for treatment of hyperproliferative diseases - Google Patents

Compositions and methods for treatment of hyperproliferative diseases Download PDF

Info

Publication number
AU773928B2
AU773928B2 AU41815/99A AU4181599A AU773928B2 AU 773928 B2 AU773928 B2 AU 773928B2 AU 41815/99 A AU41815/99 A AU 41815/99A AU 4181599 A AU4181599 A AU 4181599A AU 773928 B2 AU773928 B2 AU 773928B2
Authority
AU
Australia
Prior art keywords
agonist
rxr
compound
camp
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU41815/99A
Other languages
English (en)
Other versions
AU4181599A (en
Inventor
Gerard Benoit
Marco Gottardis
Hinrich Gronemeyer
Michel Lanotte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Louis Pasteur Strasbourg I
Institut National de la Sante et de la Recherche Medicale INSERM
Bristol Myers Squibb Co
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Louis Pasteur Strasbourg I
Institut National de la Sante et de la Recherche Medicale INSERM
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Louis Pasteur Strasbourg I, Institut National de la Sante et de la Recherche Medicale INSERM, Bristol Myers Squibb Co filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU4181599A publication Critical patent/AU4181599A/en
Application granted granted Critical
Publication of AU773928B2 publication Critical patent/AU773928B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU41815/99A 1999-04-23 1999-04-23 Compositions and methods for treatment of hyperproliferative diseases Ceased AU773928B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/008908 WO2000064260A1 (en) 1999-04-23 1999-04-23 Compositions and methods for treatment of hyperproliferative diseases

Publications (2)

Publication Number Publication Date
AU4181599A AU4181599A (en) 2000-11-10
AU773928B2 true AU773928B2 (en) 2004-06-10

Family

ID=22272621

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41815/99A Ceased AU773928B2 (en) 1999-04-23 1999-04-23 Compositions and methods for treatment of hyperproliferative diseases

Country Status (5)

Country Link
EP (1) EP1173061A1 (de)
JP (1) JP2002542268A (de)
AU (1) AU773928B2 (de)
CA (1) CA2369910A1 (de)
WO (1) WO2000064260A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078700A2 (en) * 2000-04-13 2001-10-25 Frederic Geissmann Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine
AU2002229611A1 (en) * 2000-12-08 2002-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of active compounds capable of modulating the intracellular pathway triggered by the dp receptor in langerhans cells
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
CA2705609C (en) * 2002-08-14 2016-10-25 Boston Scientific Limited Systems, methods and devices relating to delivery of medical implants
AU2003270202A1 (en) * 2002-09-17 2004-04-08 Centre National De La Recherche Scientifique Pharmaceutical compositions increasing camp useful for the treatment of cancers
GB0224415D0 (en) * 2002-10-21 2002-11-27 Medical Res Council Compositions
JPWO2004056351A1 (ja) * 2002-12-20 2006-04-20 エーザイ株式会社 Ｐｋａ活性調節剤
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020093A1 (en) * 1993-03-11 1994-09-15 Allergan, Inc. Treatment of tumors with compounds having rxr retinoid receptor agonist activity
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
WO1999063980A1 (en) * 1998-06-12 1999-12-16 Ligand Pharmaceuticals Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455265A (en) * 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
WO1994020093A1 (en) * 1993-03-11 1994-09-15 Allergan, Inc. Treatment of tumors with compounds having rxr retinoid receptor agonist activity
WO1999063980A1 (en) * 1998-06-12 1999-12-16 Ligand Pharmaceuticals Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators

Also Published As

Publication number Publication date
WO2000064260A1 (en) 2000-11-02
EP1173061A1 (de) 2002-01-23
AU4181599A (en) 2000-11-10
JP2002542268A (ja) 2002-12-10
CA2369910A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
US6653322B1 (en) Therapeutic combinations of RAR antagonists and RXR agonists and use thereof
WO1998008546A9 (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
AU773928B2 (en) Compositions and methods for treatment of hyperproliferative diseases
Chomienne et al. Retinoid differentiation therapy in promyelocytic leukemia
Hoffman et al. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid.
US6184256B1 (en) Methods and compositions for use in modulating expression of matrix metalloproteinase genes
US6624154B1 (en) Compositions and methods for treatment of hyperproliferative diseases
AU701790B2 (en) Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl}
Leal et al. Potential therapeutic uses of rexinoids
JP4435418B2 (ja) 新規レチノイドおよびその使用法
US6713515B2 (en) Retinoic acid receptor antagonists as promoters of angiogenesis
US20020090352A1 (en) Compositions and methods for use in modulating immune system function
Crowe Receptor selective synthetic retinoids as potential cancer chemotherapy agents
US6211239B1 (en) Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)
JP2004528316A (ja) 癌治療のための、レチノイド受容体リガンドおよび選択される細胞毒性剤の相乗的な組み合わせ
MXPA99001757A (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
AU2002305072A1 (en) Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
US20020048580A1 (en) Method of inducing lung branching
WO2009154873A2 (en) Use of novel lipid mediators to inhibit angiogenesis
Chomienne Molecular Basis for Retinoic Acid Effects in Acute Promyelocytic Leukemia
CHOMIENNE et al. P LEFEBVRE, N BALITRAND, S BARBEY, H DE THE, P FENAUX, L DEGOS
De Luca Retinoids in differentiation and cancer research

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)